Human NKp30/NCR3 Antibody
Human NKp30/NCR3 Antibody Summary
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Human NKp30 Antibody Induces IFN‑ gamma Secretion in NK‑92 Cells. Human NKp30 Monoclonal Antibody induces IFN-gamma secretion in the NK-92 human natural killer lymphoma cell line in a dose-dependent manner, as measured using the Human IFN-gamma DuoSet ELISA Kit (Catalog # DY285B). The ED50 for this effect is typically 0.2-1.2 µg/mL.
View Larger
Detection of NKp30/NCR3 in Human Blood Lymphocytes by Flow Cytometry. Human peripheral blood lymphocytes were stained with either (A) Mouse Anti-Human NKp30/NCR3 Monoclonal Antibody (Catalog # MAB1849) or (B) Mouse IgG2A Isotype Control (MAB003) followed by anti-Mouse IgG APC-conjugated secondary antibody (F0101B) and Mouse Anti-Human NCAM-1/CD56 PE-conjugated Monoclonal Antibody (FAB2408P). Staining was performed using our Staining Membrane-associated Proteins protocol.
View Larger
Detection of NKp30/NCR3 by Flow Cytometry beta -1,3-glucan is required for NKp30-mediated killing of Cryptococcus. g NKp30 binding to C. neoformans vs. C. albicans analyzed using flow cytometry. The experiment was performed twice. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29467448), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of NKp30/NCR3 by Flow Cytometry beta -1,3-glucan is required for NKp30-mediated killing of Cryptococcus. f Anti-NKp30 mAb (1C01) blocked NKp30 binding to beta -1,3-GB. Recombinant NKp30 was incubated with 1C01 before being applied to beads conjugated with beta -1,3-glucan. The presence of NKp30 on beta -1,3-GB was detected using the polyclonal anti-NKp30 antibody. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29467448), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of NKp30/NCR3 by Western Blot beta -1,3-glucan increases expression & clustering of NKp30 in NK. a NKp30 expression in YT in response to beta -1,3-glucan. YT treated with beta -1,3-glucan (III & IV) & expression of NKp30 using 1C01 was compared to untreated (I), or untreated labeled with isotype control (II). b WB analysis of NKp30 expression in YT in response to beta -1,3-glucan. YT incubated with or without beta -1,3-glucan for various times. The experiment was repeated three times with similar results. c NKp30 labeling at the synapse between a representative single YT cell & a single beta -1,3-glucan-conjugated bead. 1C01 was used to label NKp30. The location of the bead is shown with a white arrow. Bar = 5 µm. d Proximity of NKp30 expression in relation to the radius defined by the center of the IS (n = 21 ) in panel c. The method for determining the angle is illustrated in Supplementary Fig. 6C. Clustering was defined when the peak of fluorescence was at an angle <45° (blue bars in the left). e Frequency of NKp30 clustering of all YT cell conjugates with beta -1,3-glucan-conjugated or unconjugated beads as analyzed in panel c, as defined in panel d. f TIRF microscopic analysis of NKp30 expression at the interface between YT & beta -1,3-glucan or control. YT loaded into a glass chamber that had been coated with beta -1,3-glucan or mannan incubated at 37 °C for 30 min, fixed & stained for NKp30 using 1C01. Bar = 10 µm. g Fluorescent intensity of NKp30 from panel f in arbitrary units. Distance is defined in Supplementary Fig. 6A-B. All experiments repeated three times with similar results. TIRF total internal reflection fluorescence, poly-l-lysine coating alone or mannan coating served as control, Au arbitrary unit, Arrow bead, SD spinning disc microscopy, DIC differential interference contrast digital image, IS immunological synapse Image collected & cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29467448), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of NKp30/NCR3 by Flow Cytometry beta -1,3-glucan is required for NKp30-mediated killing of Cryptococcus. e Flow cytometric analysis of a recombinant NKp30-Fc fusion protein binding to beta -glucan-conjugated beads ( beta -1,3-GB) compared to unconjugated polystyrene beads as control. NKp30-Fc on the beads was detected with anti-NKp30 antibody (1C01). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29467448), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: NKp30/NCR3
NKp30, along with NKp44 and NKp46, constitute a group of receptors termed “Natural Cytotoxicity Receptors” (1). These receptors play a major role in triggering NK‑mediated killing of most tumor cells lines. NKp30 is a type I transmembrane protein having a single extracellular V-like immunoglobulin domain (2). A physical association with the ITAM-bearing accessory protein, CD3 zeta, occurs via a charged residue in the NKp30 transmembrane domain. Ligation of NKp30 with a specific antibody results in phosphorylation of CD3 zeta (3). NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells found in peripheral blood and spleen (4). NKp30 is absent from the CD56bright, CD16- subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up-regulated in these cells upon IL-2 activation (4). Studies with neutralizing antibodies reveal that NKp30 is partially responsible for triggering lytic activity against several tumor cell types and that it is the main receptor responsible for NK‑mediated lysis of immature dendritic cells (2, 5). The ligand(s) recognized by NKp30 has not been described.
- Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
- Pende, D. et al. (1999) J. Exp. Med. 190:1505.
- Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
- Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
- Ferlazzo, G. et al. (2002) J. Exp. Med. 195:343.
Product Datasheets
Citations for Human NKp30/NCR3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
8
Citations: Showing 1 - 8
Filter your results:
Filter by:
-
Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for beta cell replacement
Authors: R Chimienti, T Baccega, S Torchio, F Manenti, S Pellegrini, A Cospito, A Amabile, MT Lombardo, P Monti, V Sordi, A Lombardo, M Malnati, L Piemonti
Cell Reports, 2022-09-27;40(13):111423.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
Authors: N Kim, MY Kim, YU Cho, W Chen, KH Lee, HS Kim
Cancers (Basel), 2020-07-16;12(7):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and ?? T cells
Authors: Z Djaoud, LA Guethlein, A Horowitz, T Azzi, N Nemat-Gorg, D Olive, D Nadal, PJ Norman, C Münz, P Parham
J. Exp. Med., 2017-05-03;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production1
Authors: Maryam Salimi, Luzheng Xue, Helen Jolin, Clare Hardman, David J. Cousins, Andrew N. J. McKenzie et al.
The Journal of Immunology
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.
Authors: Herrmann, Julia, Berberich, Hannah, Hartmann, Jessica, Beyer, Steffen, Davies, Karen, Koch, Joachim
J Biol Chem, 2013-11-25;289(2):765-77.
Species: Human, Insect, Moth - Trichoplusia ni (Cabbage Looper), Mouse
Sample Types: Cell Culture Supernates, Whole Cells
Applications: ELISA Development, Flow Cytometry, IHC, IHC-Fr -
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Authors: Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F
Blood, 2007-10-18;111(3):1309-17.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
A novel binding assay to assess specificity of monoclonal antibodies.
Authors: Warren HS, Warren</LastName><ForeNam HS</Initia, Bettadapura J
J. Immunol. Methods, 2005-08-15;305(1):33-8.
Species: Human
Sample Types: Complex Sample Type
Applications: Epitope Mapping -
Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan.
Authors: Warren HS, Jones AL, Freeman C, Bettadapura J, Parish CR
J. Immunol., 2005-07-01;175(1):207-12.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human NKp30/NCR3 Antibody
There are currently no reviews for this product. Be the first to review Human NKp30/NCR3 Antibody and earn rewards!
Have you used Human NKp30/NCR3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
